ArticleFrontiers in immunology2022
Activation of Complement Components on Circulating Blood Monocytes From COVID-19 Patients.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Complement Activation in Maternal and Placental Pathology of Preeclampsia.Hypertension (Dallas, Tex. : 1979) · 2026Article
- Impact of complement system proteins on the clinical progression of hospitalized patients with COVID-19.BMC infectious diseases · 2025Article
- CD55 upregulation in T cells of COVID-19 patients suppresses type-I interferon responses.Communications biology · 2025Article
- SARS-CoV-2 Infection Aggravates Physical and Mental Health in Cancer Patients Compared to Co-Living Individuals.Cancer medicine · 2025Observational
- Retrospective cohort analysis on predicting pulmonary fibrosis in elderly SARS-CoV-2-infected patients.Frontiers in cellular and infection microbiology · 2025Article
- A Histological Analysis and Detection of Complement Regulatory Protein CD55 in SARS-CoV-2 Infected Lungs.Life (Basel, Switzerland) · 2024Article
- sMR and PTX3 levels associate with COVID-19 outcome and survival but not with Long COVID.iScience · 2024Article
- Prevalence of anti-lymphocyte IgM autoantibodies driving complement activation in COVID-19 patients.Frontiers in immunology · 2024Article
- Complement and complement regulatory proteins are upregulated in lungs of COVID-19 patients.Pathology, research and practice · 2023Article
- Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to know.Immunobiology · 2023Review
- Identification of human genetic variants modulating the course of COVID-19 infection with importance in other viral infections.Frontiers in genetics · 2023Article
- Editorial: The impact of COVID-19 on immune system-related complications in surgical patients.Frontiers in surgery · 2023Article
- Complement regulatory proteins: Candidate biomarkers in differentiating tuberculosis pleural effusion.Frontiers in immunology · 2023Article
- Update on Innate Immunity in Acute Kidney Injury-Lessons Taken from COVID-19.International journal of molecular sciences · 2022Review
- Functional reprogramming of monocytes in patients with acute and convalescent severe COVID-19.JCI insight · 2022Article
- Levels of soluble complement regulators predict severity of COVID-19 symptoms.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 1 country.
Funding
Abstract
The coronavirus disease-2019 (COVID-19) caused by the SARS-CoV-2 virus may vary from asymptomatic to severe infection with multi-organ failure and death. Increased levels of circulating complement biomarkers have been implicated in COVID-19-related hyperinflammation and coagulopathy. We characterized systemic complement activation at a cellular level in 49-patients with COVID-19. We found increases of the classical complement sentinel C1q and the downstream C3 component on circulating blood monocytes from COVID-19 patients when compared to healthy controls (HCs). Interestingly, the cell surface-bound complement inhibitor CD55 was also upregulated in COVID-19 patient monocytes in comparison with HC cells. Monocyte membrane-bound C1q, C3 and CD55 levels were associated with plasma inflammatory markers such as CRP and serum amyloid A during acute infection. Membrane-bounds C1q and C3 remained elevated even after a short recovery period. These results highlight systemic monocyte-associated complement activation over a broad range of COVID-19 disease severities, with a compensatory upregulation of CD55. Further evaluation of complement and its interaction with myeloid cells at the membrane level could improve understanding of its role in COVID-19 pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.